Prostate Cancer and Prostatic Diseases

FIGURES AND TABLES

FROM:

A comparison of the efficacy and tolerability of tamsulosin and finasteride in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia

P Rigatti, M Brausi, R M Scarpa, D Porru, H Schumacher and C A Rizzi for the MICTUS Study Group

BACK TO ARTICLE
Figure 1 - Unfortunately we are unable to provide accessible alternative text for this. If you require assistance to access this image, please contact help@nature.com or the author

Figure 1.

Evolution of total SPI over time.

Full figure and legend (70K)
Figure 2 - Unfortunately we are unable to provide accessible alternative text for this. If you require assistance to access this image, please contact help@nature.com or the author

Figure 2.

Evolution of storage SPI over time.

Full figure and legend (72K)
Figure 3 - Unfortunately we are unable to provide accessible alternative text for this. If you require assistance to access this image, please contact help@nature.com or the author

Figure 3.

Evolution of voiding SPI over time.

Full figure and legend (67K)
Figure 4 - Unfortunately we are unable to provide accessible alternative text for this. If you require assistance to access this image, please contact help@nature.com or the author

Figure 4.

Evolution of SPI responders over time.

Full figure and legend (79K)
Figure 5 - Unfortunately we are unable to provide accessible alternative text for this. If you require assistance to access this image, please contact help@nature.com or the author

Figure 5.

Evolution of Qmax over time.

Full figure and legend (77K)
Figure 6 - Unfortunately we are unable to provide accessible alternative text for this. If you require assistance to access this image, please contact help@nature.com or the author

Figure 6.

Effect on sexual function, as assessed by means of a sexual function questionnaire. An odds ratio greater than 1 indicates an advantage of tamsulosin over finasteride, which is statistically significant if the 95% confidence interval is completely lying above 1.

Full figure and legend (30K)
Table 1 - Effect on primary (ITT and PP) and secondary efficacy variables (ITT population) - Unfortunately we are unable to provide accessible alternative text for this. If you require assistance to access this image, please contact help@nature.com or the author

Table 1 - Effect on primary (ITT and PP) and secondary efficacy variables (ITT population).

Full table
Table 2 - Number (%) of patients with adverse events - Unfortunately we are unable to provide accessible alternative text for this. If you require assistance to access this image, please contact help@nature.com or the author

Table 2 - Number (%) of patients with adverse events.

Full table
Table 3 - [thinsp] - Unfortunately we are unable to provide accessible alternative text for this. If you require assistance to access this image, please contact help@nature.com or the author

Table 3 -  .

Full table
BACK TO ARTICLE